Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix Inc (SNGX) is a biopharmaceutical innovator developing therapies for rare diseases and biodefense solutions. This page provides official updates on clinical trials, regulatory milestones, and scientific advancements across its two core segments: specialized therapeutics for conditions like cutaneous T-cell lymphoma (CTCL) and public health vaccines for biological threats.
Investors and researchers will find timely announcements about HyBryte™ photodynamic therapy progress, ThermoVax® platform developments, and partnership updates. Content spans trial results, FDA designations, manufacturing collaborations, and research publications – all essential for understanding SNGX's position in niche therapeutic markets.
Bookmark this page for structured access to Soligenix's verified news, organized to help stakeholders monitor advancements in orphan drug candidates and heat-stable vaccine technologies. Regular updates ensure you stay informed about this innovator's progress in addressing high-need, low-competition medical challenges.
Soligenix announced significant progress in its Phase 3 FLASH study of SGX301 for treating cutaneous T-cell lymphoma (CTCL). Continued treatment for 6 months showed a 49% response rate, increasing from 40% in the previous cycle. Key findings include effective treatment of both patch and plaque lesions, with 66% of patients opting for extended therapy. The drug's safety profile remains robust, with no systemic hypericin detected. Soligenix is preparing for FDA application while targeting commercialization or partnerships for SGX301, emphasizing its potential as a transformative therapy.
Soligenix, a late-stage biopharmaceutical company, announced that Christopher J. Schaber, Ph.D., its CEO, will present at the BIO Investor Forum from October 13-15, 2020. The presentation will be available on-demand for attendees. Soligenix focuses on developing products for rare diseases, including SGX301 for cutaneous T-cell lymphoma and dusquetide for oral mucositis in head and neck cancer. Their Public Health Solutions segment includes a ricin toxin vaccine and other vaccine candidates for emerging infectious diseases. For more details, visit www.soligenix.com.
Soligenix, Inc. (Nasdaq: SNGX) announced the publication of nonclinical results on filovirus protein antigens, including for Ebola and Marburg viruses, revealing successful thermostabilization. Collaborative research with the University of Colorado and University of Hawaiʻi at Mānoa indicates that heat-stable vaccine formulations can be developed, maintaining stability for 12 weeks at 40°C. The company aims to expedite its Marburg virus vaccine evaluations. This advancement aligns with their joint COVID-19 vaccine effort, CiVax™, to enhance vaccine distribution reliability in regions with unstable power supplies.
Soligenix, Inc. (Nasdaq: SNGX) hosted an investor webcast on September 10, 2020, showcasing its COVID-19 vaccine candidate, CiVax™, developed from its thermostabilized glycoprotein vaccine platform. Collaborating with the University of Hawaiʻi, the platform focuses on multivalent vaccines, showing potential for broad applicability, particularly for vulnerable populations. Preclinical results indicate strong immune responses following vaccination. The company aims to address urgent needs for effective COVID-19 prevention amidst the pandemic.
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, announces that its CEO, Christopher J. Schaber, PhD, will present at two upcoming virtual investor conferences. The first is the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 1:20 PM ET, with a live presentation available online. The second is the Lake Street Capital Markets' 4th Annual Best Ideas Growth Conference on September 17, 2020, which includes one-on-one and group meetings. Soligenix focuses on developing treatments for rare diseases and has multiple ongoing programs.
Soligenix, Inc. (SNGX) announced an Investor Webcast Event on September 10, 2020, to discuss its CiVax™ COVID-19 vaccine development using a thermostabilized glycoprotein platform. The prototype vaccine demonstrates strong immunity induction in preclinical studies, with notable safety in high-risk populations. Combined with its ability to remain stable at high temperatures, CiVax™ aims to meet urgent vaccination needs. Experts will present, followed by a Q&A session. The event invites questions beforehand and will provide a recording post-webcast.
Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company focused on rare diseases, announced that its CFO, Jonathan Guarino, will present at the LD Micro Conference from September 1-4, 2020. Guarino's presentation is scheduled for September 4 at 9:40 AM ET. The conference will be held virtually. The company specializes in developing treatments like SGX301 for cutaneous T-cell lymphoma and vaccine candidates for various diseases. For more details on the conference, visit LD Micro Conference.
Soligenix, Inc. (SNGX) announced its Q2 2020 financial results and recent accomplishments. Revenue was $0.5 million, down from $1.4 million in Q2 2019. Net loss increased to $2.8 million, or ($0.10) per share, primarily due to higher R&D costs ($2.2 million). Positive developments include significant results from the Phase 3 FLASH trial for SGX301, with a statistically significant treatment response (p=0.04). Enrollment was completed for the SGX942 trial, with top-line results expected in Q4 2020. The company maintains a cash position of approximately $11.2 million, bolstered by government funding.
Soligenix, Inc. (SNGX) announced positive results from pre-clinical studies for its CiVax™ COVID-19 vaccine, demonstrating rapid onset immunity with antibody responses detected within 14 days of vaccination. Collaborations with the University of Hawaiʻi at Mānoa highlighted the efficacy of the CoVaccine HT™ adjuvant in enhancing immune responses. The vaccine aims to simplify distribution by being heat stable, which could alleviate cold chain logistics. The findings have been submitted for peer review in the journal npj Vaccines, reinforcing Soligenix's commitment to developing safe and effective vaccines for COVID-19.
Soligenix has completed patient enrollment for its Phase 3 DOM-INNATE study of SGX942, targeting oral mucositis in head and neck cancer patients. A total of 268 subjects were enrolled following positive interim analysis by an independent Data Monitoring Committee (DMC), which confirmed a beneficial drug effect. With top-line results expected in Q4 2020, SGX942 aims to address a significant unmet need as no FDA-approved treatment currently exists for this condition. The company maintains approximately $8 million in cash, positioning for further development milestones.
FAQ
What is the current stock price of Soligenix (SNGX)?
What is the market cap of Soligenix (SNGX)?
